The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Login
EN
+7 (495) 482-4118
+7 (495) 482-4329
+8 800 250-18-12
  • (toll-free number for subscriptions)
    Mon-Fri from 10 a.m. to 6 p.m.

  • © 1998-2026
+7 (495) 482-43-29
EN
All journals
Journal
Year
Year
Search result: 0

Journal: Evidence-based Cardiology. 2017;10(3): 27‑37

Read: 1031 times

Download PDF (RU)
Contact the author
Table of contents

To cite this article:

. Evidence-based Cardiology. 2017;10(3):27‑37. (In Russ.)

МСФ на ЯМ
Использование инфографики авторами научных работ
Close metadata
Abstract:

Close metadata

References:

  1. Centers for Disease Control and Prevention. Mission, role and pledge (http:// www.cdc.gov/about/organization/ mission.htm).
  2. Rothwell P.M. External validity of randomised controlled trials: “to whom do the results of this trial apply?” Lancet 2005;365:82—93.
  3. Jones D.S., Podolsky S.H. The history and fate of the gold standard. Lancet 2015;385:1502—1503.
  4. Bothwell L.E., Greene J.A., Podolsky S.H., Jones D.S. Assessing the gold standard — lessons from the history of RCTs. N Engl J Med 2016;374:2175—2181.
  5. Kones R., Rumana U., Merino J. Exclusion of ‘nonRCT evidence’ in guidelines for chronic diseases — is it always appropriate? The Look AHEAD study. Curr Med Res Opin 2014;30:2009—2019.
  6. Chavez-MacGregor M., Giordano S.H. Randomized clinical trials and observational studies: is there a battle? J Clin Oncol 2016;34:772—773.
  7. Deaton A. Instruments, randomization, and learning about development. J Econ Lit 2010;48:424—455.
  8. Woodcock J., Ware J.H., Miller P.W., et al. Clinical trial series. N Engl J Med 2016;374:2167.
  9. Mitchell E.A., Scragg R., Stewart A.W., et al. Results from the first year of the New Zealand Cot Death Study. N Z Med J 1991;104:71—76.
  10. Irving M., Eramudugolla R., Cherbuin N., Anstey K.J. A critical review of grading systems: implications for public health policy. Eval Health Prof 2016 May 10 [Epub ahead of print].
  11. Sacks H., Chalmers T.C., Smith H. Jr. Randomized versus historical controls for clinical trials. Am J Med 1982;72:233—240.
  12. Jackson L.A., Jackson M.L., Nelson J.C., et al. Evidence of bias in estimates of influenza vaccine effectiveness in seniors. Int J Epidemiol 2006;35: 337—344.
  13. Concato J., Shah N., Horwitz R.I. Randomized, controlled trials, observational studies, and the hierarchy of research designs. N Engl J Med 2000;342:1887—1892.
  14. Golfam M., Beall R., Brehaut J., et al. Comparing alternative design options for chronic disease prevention interventions. Eur J Clin Invest 2015;45:87—99.
  15. Grodstein F., Stampfer M.J., Manson J.E., et al. Postmenopausal estrogen and progestin use and the risk of cardiovascular disease. N Engl J Med 1996;335:453—461.
  16. Rossouw J.E., Anderson G.L., Prentice R.L., et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women’s Health Initiative randomized controlled trial. JAMA 2002;288:321—333.
  17. Prentice R.L., Langer R., Stefanick M.L., et al. Combined postmenopausal hormone therapy and cardiovascular disease: toward resolving the discrepancy between observational studies and the Women’s Health Initiative clinical trial. Am J Epidemiol 2005;162:404—414.
  18. Prentice R.L., Langer R.D., Stefanick M.L., et al. Combined analysis of Women’s Health Initiative observational and clinical trial data on postmenopausal hormone treatment and cardiovascular disease. Am J Epidemiol 2006;163:589—599.
  19. Manson J.E., Chlebowski R.T., Stefanick M.L., et al. Menopausal hormone therapy and health outcomes during the intervention and extended poststopping phases of the Women’s Health Initiative randomized trials. JAMA 2013;310:1353—1368.
  20. Vandenbroucke J.P. The HRT controversy: observational studies and RCTs fall in line. Lancet 2009;373:1233—1235.
  21. Mendelsohn M.E., Karas R.H. HRT and the young at heart. N Engl J Med 2007;356:2639—2641.
  22. Nasal influenza vaccine approved for younger children. Food and Drug Administration Consumer Updates. September 26, 2007 (https://www.fda.gov/ForConsumers/ConsumerUpdates/ucm048715.htm).
  23. Ashkenazi S., Vertruyen A., Arístegui J., et al. Superior relative efficacy of live attenuated inf luenza vaccine compared with inactivated influenza vaccine in young children with recurrent respiratory tract infections. Pediatr Infect Dis J 2006; 25:870—879.
  24. Fleming D.M., Crovari P., Wahn U., et al. Comparison of the efficacy and safety of live attenuated cold-adapted influenza vaccine, trivalent, with trivalent inactivated influenza virus vaccine in children and adolescents with asthma. Pediatr Infect Dis J 2006;25:860—869.
  25. Belshe R.B., Edwards K.M., Vesikari T., et al. Live attenuated versus inactivated influenza vaccine in infants and young children. N Engl J Med 2007;356:685—696.
  26. Grohskopf L.A., Olsen S.J., Sokolow L.Z., et al. Prevention and control of seasonal influenza with vaccines: recommendations of the Advisory Committee on Immunization Practices (ACIP) — United States, 2014–15 influenza season. MMWR Morb Mortal Wkly Rep 2014;63:691—697.
  27. Gaglani M., Pruszynski J., Murthy K., et al. Influenza vaccine effectiveness against the 2009 Pandemic A (H1N1) virus differed by vaccine-type during 2013-14 in the United States. J Infect Dis 2016;213:1546—1556.
  28. Flannery B. Update on effectiveness of live-attenuated versus inactivated influenza vaccines in children and adolescents aged 2-18 years – US Flu VE Network. Presented at the Meeting of the Advisory Committee on Immunization Practices, Atlanta, October 29—30, 2014 (http://www .nitag-resource.org/uploads/media/default/0001/02/a4c56839e81370e3d 8635468 dddee24ac681d2da.pdf ).
  29. Chung J.R., Flannery B., Thompson M.G., et al. Seasonal effectiveness of live attenuated and inactivated influenza vaccine. Pediatrics 2016;137(2):e20153279.
  30. ACIP votes down use of LAIV for 2016-2017 flu season. Media statement from the Centers for Disease Control and Prevention, June 22, 2016 (http://www.cdc .gov/media/releases/2016/s0622-laiv-flu.html).
  31. Streptomycin in Tuberculosis Trials Committee. Streptomycin treatment of pulmonary tuberculosis. Br Med J 1948;2:769—782.
  32. Iseman M.D., Sbarbaro J.A. Short-course chemotherapy of tuberculosis: hail Britannia (and friends)! Am Rev Respir Dis 1991;143:697—698.
  33. Mitchison D.A. The diagnosis and therapy of tuberculosis during the past 100 years. Am J Respir Crit Care Med 2005;171:699—706.
  34. Fox W. Self-administration of medicaments: a review of published work and a study of the problems. Bull Int Union Tuberc 1962;32:307—331.
  35. Dawson J.J.Y., Devadatta S., Fox W., et al. A 5-year study of patients with pulmonary tuberculosis in a concurrent comparison of home and sanatorium treatment for one year with isoniazid plus PAS. Bull World Health Organ 1966;34:533—551.
  36. Treatment of tuberculosis: guidelines for national programmes. Geneva: World Health Organization, 1997.
  37. Zwarenstein M., Schoeman J.H., Vundule C., et al. Randomised controlled trial of self-supervised and directly observed treatment of tuberculosis. Lancet 1998;352:1340—1343.
  38. Akkslip S., Rasmithat S., Maher D., Sawert H. Direct observation of tuberculosis treatment by supervised family members in Yasothorn Province, Thailand. Int J Tuberc Lung Dis 1999;3:1061—1065.
  39. Sterling T.R., Lehmann H.P., Frieden T.R. Impact of DOTS compared with DOTS-plus on multidrug resistant tuberculosis and tuberculosis deaths: decision analysis. BMJ 2003;326:574.
  40. Moonan P.K., Quitugua T.N., Pogoda J.M., et al. Does directly observed therapy (DOT) reduce drug resistant tuberculosis? BMC Public Health 2011;11:19.
  41. Frieden T.R., Sherman L.F., Maw K.L., et al. A multi-institutional outbreak of highly drug-resistant tuberculosis: epidemiology and clinical outcomes. JAMA 1996; 276:1229—1235.
  42. Xu J.Q., Murphy S.L., Kochanek K.D., Bastian B.A. Deaths: final data for 2013. Natl Vital Stat Rep 2016;64(2):1—119.
  43. Nwankwo T., Yoon S.S., Burt V., Gu Q. Hypertension among adults in the United States: National Health and Nutrition Examination Survey, 2011—2012. NCHS Data Brief 2013;133:1—8.
  44. Institute of Medicine. Strategies to reduce sodium intake in the United States. Washington, DC: National Academies Press, 2010.
  45. Mozaffarian D., Fahimi S., Singh G.M., et al. Global sodium consumption and death from cardiovascular causes. N Engl J Med 2014;371:624—634.
  46. He F.J., Pombo-Rodrigues S., MacGregor G.A. Salt reduction in England from 2003 to 2011: its relationship to blood pressure, stroke and ischaemic heart disease mortality. BMJ Open 2014; 4(4):e004549.
  47. He F.J., MacGregor G.A. Salt reduction lowers cardiovascular risk: meta-analysis of outcome trials. Lancet 2011;378:380—382.
  48. Cook N.R., Appel L.J., Whelton P.K. Sodium intake and all-cause mortality over 20 years in the trials of hypertension prevention. J Am Coll Cardiol 2016;68:1609—1617.
  49. Mente A., O’Donnell M., Rangarajan S., et al. Associations of urinary sodium excretion with cardiovascular events in individuals with and without hypertension: a pooled analysis of data from four studies. Lancet 2016;388:465—475.
  50. Graudal N., Jürgens G., Baslund B., Alderman M.H. Compared with usual sodium intake, low- and excessive-sodium diets are associated with increased mortality: a meta-analysis. Am J Hypertens 2014;27:1129—1137.
  51. O’Donnell M., Mente A., Rangarajan S., et al. Urinary sodium and potassium excretion, mortality, and cardiovascular events. N Engl J Med 2014;371:612—623.
  52. Cobb L.K., Anderson C.A., Elliott P., et al. Methodological issues in cohort studies that relate sodium intake to cardiovascular disease outcomes: a science advisory from the American Heart Association. Circulation 2014;129:1173—1186.
  53. Willett W. Nutritional epidemiology: monographs in epidemiology and biostatistics. 3rd ed. New York: Oxford University Press, 2013.
  54. He F.J, MacGregor G.A. Hypertension: salt: flawed research should not divert actions to reduce intake. Nat Rev Nephrol 2016;12:514—515.
  55. Cogswell M.E., Maalouf J., Elliott P., et al. Use of urine biomarkers to assess sodium intake: challenges and opportunities. Annu Rev Nutr 2015;35:349—387.
  56. Rakova N., Jüttner K., Dahlmann A., et al. Long-term space flight simulation reveals infradian rhythmicity in human Na(+) balance. Cell Metab 2013;17:125—131.
  57. Cogswell M.E., Mugavero K., Bowman B.A., Frieden T.R. Dietary sodium and cardiovascular disease risk — measurement matters. N Engl J Med 2016;375:580—586.
  58. Multiple Risk Factor Intervention Trial Group. The Multiple Risk Factor Intervention Trial (MRFIT): a national study of primary prevention of coronary heart disease. JAMA 1976;235:825—827.
  59. Frieden T.R. Sodium reduction — saving lives by putting choice into consumers’ hands. JAMA 2016;316:579—580.
  60. Schieppati A., Henter J.-I., Daina E., Aperia A. Why rare diseases are an important medical and social issue. Lancet 2008;371:2039—2041.
  61. Griggs R.C., Batshaw M., Dunkle M., et al. Clinical research for rare disease: op- portunities, challenges, and solutions. Mol Genet Metab 2009;96:20—26.
  62. Rubinstein Y.R., Groft S.C., Bartek R., et al. Creating a global rare disease patient registry linked to a rare diseases biorepository database: Rare Disease-HUB (RD-HUB). Contemp Clin Trials 2010;31:394—404.
  63. Frakt A.B. An observational study goes where randomized clinical trials have not. JAMA 2015;313:1091—1092.
  64. Lederle F.A., Cushman W.C., Ferguson R.E., et al. Chlorthalidone versus hydrochlorothiazide: a new kind of Veterans Affairs cooperative study. Ann Intern Med 2016;165:663—664.
  65. Ernst M.E., Lund B.C. Renewed interest in chlorthalidone: evidence from the Veterans Health Administration. J Clin Hypertens (Greenwich) 2010;12:927—934.
  66. Roush G.C., Holford T.R., Guddati A.K. Chlorthalidone compared with hydrochlorothiazide in reducing cardiovascular events: systematic review and network meta-analyses. Hypertension 2012;59: 1110—1117.
  67. ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 2002;288:2981—2997.
  68. Dorsch M.P., Gillespie B.W., Erickson S.R., et al. Chlorthalidone reduces cardiovascular events compared with hydrochlorothiazide: a retrospective cohort analysis. Hypertension 2011;57:689—694.
  69. Woolever D.R. The art and science of clinical decision making. Fam Pract Manag 2008;15:31—36.
  70. Groopman J. How doctors think. Boston: Houghton Mifflin, 2007.
  71. Angus D.C. Fusing randomized trials with big data: the key to self-learning health care systems? JAMA 2015;314:767—768.
  72. Thall P.F., Wathen J.K. Practical Bayesian adaptive randomisation in clinical trials. Eur J Cancer 2007;43:859—866.
  73. Moss A.J., Francis C.W., Ryan D. Collaborative clinical trials. N Engl J Med 2011;364:789—791.
  74. Bhatt D.L., Mehta C. Adaptive designs for clinical trials. N Engl J Med 2016;375:65—74.
  75. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet 2002;360:7—22.
  76. Sever P.S., Dahlöf B., Poulter N.R., et al. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial — Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet 2003;361:1149—1158.
  77. Colhoun H.M., Betteridge D.J., Durrington P.N., et al. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. Lancet 2004;364:685—696.
  78. Khan M., Qureshi A.I. Factors associated with increased rates of post-procedural stroke or death following carotid artery stent placement: a systematic review. J Vasc Interv Neurol 2014;7:11—20.
  79. Baigent C., Keech A., Kearney P.M., et al. Efficacy and safety of cholesterol-lower- ing treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet 2005;366:1267—1278.
  80. Cholesterol Treatment Trialists’ (CTT) Collaboration. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet 2010;376:1670—1681.
  81. Schrag D., Kuntz K.M., Garber J.E., Weeks J.C. Decision analysis — effects of prophylactic mastectomy and oophorectomy on life expectancy among women with BRCA1 or BRCA2 mutations. N Engl J Med 1997;336:1465—1471.
  82. Zauber A.G., Lansdorp-Vogelaar I., Knudsen A.B., et al. Evaluating test strategies for colorectal cancer screening: a decision analysis for the U.S. Preventive Services Task Force. Ann Intern Med 2008;149:659—669.
  83. Hayes J.H., Ollendorf D.A., Pearson S.D., et al. Active surveillance compared with initial treatment for men with low-risk prostate cancer: a decision analysis. JAMA 2010;304:2373—2380.
  84. Tai V., Grey A., Bolland M.J. Results of observational studies: analysis of findings from the Nurses’ Health Study. PLoS One 2014;9(10):e110403.
  85. Niederau C., Lange S., Heintges T., et al. Prognosis of chronic hepatitis C: results of a large, prospective cohort study. Hepatology 1998;28:1687—1695.
  86. Zou B., Li T., Zhou Q., et al. Adjuvant therapeutic modalities in primary small cell carcinoma of esophagus patients: a retrospective cohort study of multicenter clinical outcomes. Medicine (Baltimore) 2016;95(17):e3507.
  87. Mulrooney D.A., Yeazel M.W., Kawashima T., et al. Cardiac outcomes in a cohort of adult survivors of childhood and adolescent cancer: retrospective analysis of the Childhood Cancer Survivor Study cohort. BMJ 2009;339:b4606.
  88. Gottlieb S.L., Newbern E.C., Griffin P.M., et al. Multistate outbreak of listeriosis linked to turkey deli meat and subsequent changes in US regulatory policy. Clin Infect Dis 2006;42:29—36.
  89. D’Souza G., Kreimer A.R., Viscidi R., et al. Case—control study of human papillomavirus and oropharyngeal cancer. N Engl J Med 2007;356:1944—1956.
  90. Cohen A.T., Tapson V.F., Bergmann J.-F., et al. Venous thromboembolism risk and prophylaxis in the acute hospital care setting (ENDORSE study): a multinational cross-sectional study. Lancet 2008;371:387—394.
  91. Mastrangelo G., Fedeli U., Visentin C., et al. Pattern and determinants of hospitalization during heat waves: an ecologic study. BMC Public Health 2007;7:200.
  92. Fairall L., Bachmann M.O., Lombard C., et al. Task shifting of antiretroviral treatment from doctors to primary-care nurses in South Africa (STRETCH): a pragmatic, parallel, cluster-randomised trial. Lancet 2012;380:889—898.
  93. Wisotzky M., Albuquerque M., Pechacek T.F., Park B.Z. The National Tobacco Control Program: focusing on policy to broaden impact. Public Health Rep 2004;119:303—310.
  94. Pneumocystis pneumonia — Los Angeles. MMWR Morb Mortal Wkly Rep 1981;30:250—252.
  95. Schuler-Faccini L., Ribeiro E.M., Feitosa I.M., et al. Possible association between Zika virus infection and microcephaly — Brazil, 2015. MMWR Morb Mortal Wkly Rep 2016;65:59—62.
  96. Fleming A. On the antibacterial action of cultures of a Penicillium, with special reference to their use in the isolation of B. influenzae. Br J Exp Pathol 1929;10:226—236.
  97. Shroff G.R., Frederick P.D., Herzog C.A. Renal failure and acute myocardial infarction: clinical characteristics in patients with advanced chronic kidney disease, on dialysis, and without chronic kidney disease: a collaborative project of the United States Renal Data System/National Institutes of Health and the National Registry of Myocardial Infarction. Am Heart J 2012;163:399—406.
  98. Benza R.L., Miller D.P., Gomberg-Maitland M., et al. Predicting survival in pulmonary arterial hypertension: insights from the Registry to Evaluate Early and Long-Term Pulmonary Arterial Hypertension Disease Management (REVEAL). Circulation 2010;122:164—172.
Contact the author
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.

Email Confirmation

An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

Email Confirmation

Contact us
If you have any questions, complaints or suggestions, please use this feedback form.
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.
Submit Application

You can become an author of one of our magazines, send a request and we will consider it in during the day.

Name
Phone
E-mail
Message
Login
Registration
E-mail
Password
Forgot Password?

Log in to the site using your account in one of the services

Password recovery
E-mail
Login
Register

We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.